Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057980 · ClinicalTrials.gov registry record · Phase 1
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00057980: Completed Phase 1 study, sponsored by Northwestern University.
NCT00057980 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057980, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining celecoxib with epirubicin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of epirubicin when given together with celecoxib and to see how well it works in treating patients with hepatocellular carcinoma (liver cancer).
Interventions
- DRUG epirubicin hydrochloride
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
What the finished NCT00057980 record still lists
NCT00057980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which epirubicin hydrochloride is the first listed.
NCT00057980 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057980 about?
NCT00057980 is a clinical study titled "Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma". RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining celecoxib with epirubicin may kill more tumor cells. PURPOSE: This phase I/II trial is ...
What is the current status of trial NCT00057980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2002-10. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00057980?
The interventions under investigation include: epirubicin hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00057980?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057980's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia